News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
760,829 Results
Type
Article (45669)
Company Profile (295)
Press Release (714847)
Multimedia
Podcasts (130)
Webinars (25)
Section
Business (213800)
Career Advice (2201)
Deals (37029)
Drug Delivery (141)
Drug Development (83839)
Employer Resources (177)
FDA (17403)
Job Trends (15670)
News (361815)
Policy (34768)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2713)
Accelerated approval (44)
Adcomms (29)
Allergies (174)
Alliances (52409)
ALS (200)
Alzheimer's disease (1792)
Antibody-drug conjugate (ADC) (401)
Approvals (17721)
Artificial intelligence (639)
Autoimmune disease (241)
Automation (52)
Bankruptcy (373)
Best Places to Work (12015)
BIOSECURE Act (20)
Biosimilars (217)
Biotechnology (186)
Bladder cancer (181)
Brain cancer (69)
Breast cancer (704)
Cancer (5538)
Cardiovascular disease (465)
Career advice (1867)
Career pathing (41)
CAR-T (325)
CDC (60)
Celiac Disease (2)
Cell therapy (862)
Cervical cancer (43)
Clinical research (72179)
Collaboration (2038)
Company closure (4)
Compensation (1316)
Complete response letters (79)
COVID-19 (2842)
CRISPR (108)
C-suite (1055)
Cystic fibrosis (153)
Data (7271)
Decentralized trials (3)
Denatured (39)
Depression (163)
Dermatology (70)
Diabetes (576)
Diagnostics (7096)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (309)
Drug pricing (215)
Drug shortages (35)
Duchenne muscular dystrophy (279)
Earnings (94187)
Editorial (63)
Employer branding (21)
Employer resources (156)
Events (123779)
Executive appointments (1085)
FDA (20994)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (32)
Funding (1694)
Gene editing (225)
Generative AI (55)
Gene therapy (713)
GLP-1 (1109)
Government (4960)
Grass and pollen (8)
Guidances (403)
Healthcare (19671)
HIV (77)
Huntington's disease (54)
IgA nephropathy (93)
Immunology and inflammation (290)
Immuno-oncology (91)
Indications (164)
Infectious disease (3176)
Inflammatory bowel disease (207)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (285)
Interviews (342)
IPO (17140)
IRA (53)
Job creations (3989)
Job search strategy (1561)
JPM (65)
Kidney cancer (18)
Labor market (94)
Layoffs (592)
Leadership (36)
Legal (8456)
Liver cancer (103)
Longevity (29)
Lung cancer (737)
Lymphoma (415)
Machine learning (54)
Management (62)
Manufacturing (1013)
MASH (182)
Medical device (14745)
Medtech (14830)
Mergers & acquisitions (21085)
Metabolic disorders (1505)
mRNA (194)
Multiple sclerosis (178)
NASH (17)
Neurodegenerative disease (407)
Neuropsychiatric disorders (101)
Neuroscience (3253)
Neurotech (1)
NextGen: Class of 2026 (6821)
Non-profit (4626)
Now hiring (74)
Obesity (722)
Opinion (312)
Ovarian cancer (196)
Pain (248)
Pancreatic cancer (268)
Parkinson's disease (356)
Partnered (34)
Patents (578)
Patient recruitment (627)
Peanut (63)
People (61703)
Pharmaceutical (71)
Pharmacy benefit managers (33)
Phase 1 (22536)
Phase 2 (31738)
Phase 3 (23665)
Pipeline (7517)
Policy (330)
Postmarket research (2643)
Preclinical (9548)
Press Release (71)
Prostate cancer (286)
Psychedelics (52)
Radiopharmaceuticals (324)
Rare diseases (1049)
Real estate (6393)
Recruiting (71)
Regulatory (26574)
Reports (54)
Research institute (2500)
Resumes & cover letters (371)
Rett syndrome (34)
RNA editing (19)
RSV (91)
Schizophrenia (171)
Series A (284)
Series B (211)
Service/supplier (14)
Sickle cell disease (109)
Special edition (26)
Spinal muscular atrophy (171)
Sponsored (49)
Startups (3865)
State (2)
Stomach cancer (18)
Supply chain (132)
Tariffs (97)
The Weekly (88)
Vaccines (1136)
Venture capital (103)
Weight loss (476)
Women's health (116)
Worklife (21)
Date
Today (146)
Last 7 days (593)
Last 30 days (2674)
Last 365 days (30953)
2026 (9209)
2025 (31035)
2024 (36218)
2023 (41203)
2022 (52475)
2021 (57191)
2020 (55783)
2019 (48575)
2018 (36640)
2017 (33856)
2016 (33443)
2015 (39499)
2014 (33079)
2013 (28253)
2012 (30499)
2011 (31057)
2010 (28926)
Location
Africa (804)
Alabama (91)
Alaska (7)
Arizona (348)
Arkansas (15)
Asia (42875)
Australia (7064)
California (12637)
Canada (3617)
China (1313)
Colorado (545)
Connecticut (550)
Delaware (385)
Europe (94228)
Florida (1890)
Georgia (411)
Hawaii (4)
Idaho (65)
Illinois (1035)
India (85)
Indiana (594)
Iowa (23)
Japan (515)
Kansas (135)
Kentucky (49)
Louisiana (39)
Maine (87)
Maryland (1531)
Massachusetts (9065)
Michigan (375)
Minnesota (702)
Mississippi (7)
Missouri (154)
Montana (35)
Nebraska (29)
Nevada (140)
New Hampshire (88)
New Jersey (3385)
New Mexico (30)
New York (3319)
North Carolina (1656)
North Dakota (10)
Northern California (6283)
Ohio (382)
Oklahoma (25)
Oregon (46)
Pennsylvania (2550)
Puerto Rico (28)
Rhode Island (51)
South America (1214)
South Carolina (83)
South Dakota (2)
Southern California (4942)
Tennessee (202)
Texas (2015)
United States (45041)
Utah (382)
Vermont (1)
Virginia (314)
Washington D.C. (81)
Washington State (1029)
West Virginia (4)
Wisconsin (128)
Wyoming (2)
760,829 Results for "aspen surgical products inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Aspen’s $115M Series C Opens Doors to Late-Stage Development for Parkinson’s Program
Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy to the market.
November 20, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Hubly Surgical awarded Breakthrough Technology Designation for Neurosurgical Products with Premier, Inc.
March 3, 2026
·
2 min read
Press Releases
Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson’s Disease
March 13, 2026
·
2 min read
Press Releases
Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases
March 18, 2026
·
5 min read
Press Releases
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
November 21, 2025
·
4 min read
Press Releases
Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
January 9, 2026
·
4 min read
Press Releases
Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
January 8, 2026
·
4 min read
Press Releases
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
March 11, 2026
·
6 min read
Press Releases
Aspen Medical Products Acquires Advanced Orthopaedics
January 30, 2025
·
2 min read
Deals
Aspen Surgical Acquires Symmetry Surgical
Aspen Surgical Products, Inc. (“Aspen”), a portfolio company of Audax Private Equity (“Audax”) and a leader in disposable surgical products, announced the acquisition of Symmetry Surgical (“Symmetry”) from RoundTable Healthcare Partners. Symmetry represents Aspen’s 15th acquisition in total and sixth since Audax’ initial investment in Aspen in 2019.
October 27, 2022
·
5 min read
1 of 76,083
Next
